Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460132 | 0.84 | L3MBTL1 (0.62) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5457869 | 0.80 | L3MBTL1 (0.50) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5450903 | 0.78 | L3MBTL1 (0.58) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5454130 | 0.78 | L3MBTL1 (0.66) | POLBKMT2AMEN1L3MBTL1PAX8 | |
| SCHEMBL5460249 | 0.78 | KMT2A (0.65) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5453078 | 0.77 | KMT2A (0.80) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5454292 | 0.76 | KMT2A (0.76) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5450725 | 0.76 | NTRK1 (0.64) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL16445880 | 0.76 | KMT2A (0.68) | POLBKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5459968 | 0.75 | KMT2A (0.71) | KMT2AMEN1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1294707-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-03-26 | — | — | EP | claimed |
| WO-2001098290-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | POLB 404/4885KMT2A 4785/4885MEN1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.